Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1861752

Meda AB - Product Pipeline Review - Q2 2011

Description:

Meda AB – Product Pipeline Review – Q2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Meda AB - Product Pipeline Review - Q2 2011” provides data on the Meda AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Meda AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Meda AB and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Meda AB - Brief Meda AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Meda AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Meda AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Meda AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Meda AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Meda AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Meda AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Meda AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Meda AB and identify potential opportunities in those areas.

Contents:

List of Tables
List of Figures
Meda AB Snapshot
Meda AB Overview
Key Information
Key Facts
Meda AB – Research and Development Overview
Key Therapeutic Areas
Meda AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Meda AB – Pipeline Products Glance
Meda AB – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Meda AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Meda AB – Drug Profiles
Dymista
Product Description
Mechanism of Action
R&D Progress
Onsolis
Product Description
Mechanism of Action
R&D Progress
Sotirimod
Product Description
Mechanism of Action
R&D Progress
Meda AB – Pipeline Analysis
Meda AB – Pipeline Products by Therapeutic Class
Meda AB - Pipeline Products By Target
Meda AB – Pipeline Products by Route of Administration
Meda AB – Pipeline Products by Molecule Type
Meda AB – Recent Pipeline Updates
Meda AB – Company Statement
Meda AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Meda AB, Deals Volume Summary, 2004 to YTD 2011
Meda AB, Deals Summary By Region, 2004 to YTD 2011
Meda AB, Deals Summary, 2004 to YTD 2011
Meda AB Detailed Deal Summary
Asset Purchase
Meda Acquires Rights Of Onsolis From BioDelivery Sciences International
Meda Acquires European Business Operations Of Valeant Pharmaceuticals
Meda Acquires Global Rights Of Pharmaceutical Products From Roche
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Meda Acquires European Rights Of Sotirimod From 3M
Meda Acquires CNS & Cancer Drugs In Europe From Wyeth
Meda Acquires European Pharmaceuticals Division Of 3M
Laboratorios Almirall Acquires Rights And Intellectual Property Of Novolizer From Meda
Meda Acquires European Rights Of Parlodel From Novartis
Meda Acquires Rights Of Imovane From Sanofi-Aventis
Meda Acquires Rights To Cibacen And Cibadrex From Novartis
Meda Acquires Rights Of Cyklokapron And Cyklo-F From Omega Pharma
Acquisition
Meda Acquires Ellem Lakemedel
Meda Acquires Recip From Recipharm
Meda Acquires MedPointe From The Carlyle, The Cypress, Ferrer Freeman And Frazier Healthcare
Meda Acquires VIATRIS From Advent International
BioPhausia Acquires Cross Pharma From Meda
Meda Acquires Ipex Medical
Equity Offering
Meda Completes Rights Offering Of $212 Million
Meda Completes Rights Offering Of $270 Million
Meda Completes Public Offering Of $324 Million
Meda Completes Public Offering Of $80 Million
Meda Expands Co-Marketing Agreement With Ethypharm
Meda Enters Into Co-Development Agreement With Cipla
BioDelivery Sciences Amends Co-Marketing Agreement With Meda
Meda Enters Into An Agreement With ULURU
Meda Extends Its Collaboration Agreement With Recordati
Valeant Pharmaceuticals Enters Into Joint Venture With Meda
BioDelivery Sciences Expands Co-Development Agreement With Meda
Meda Extends Its Agreement With Recordati
Meda Enters Into An Agreement With Ethypharm
Recordati Signs Agreement With Meda
Biodelivery Sciences International Enters Into An Agreement With Meda
Meda Enters Into Agreement With Orion Pharma
Licensing Agreements
EpiCept Enters Into Licensing Agreement With Meda
Biodelivery Sciences International Enters Into Licensing Agreement With Meda
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Meda AB – Pipeline by Therapy Area and Indication, 2011
Meda AB – Pipeline by Stage of Development, 2011
Meda AB – Monotherapy Products in Pipeline, 2011
Meda AB – Filed, 2011
Meda AB - Phase II, 2011
Meda AB - Pipeline By Therapeutic Class, 2011
Meda AB - Pipeline By Target, 2011
Meda AB – Pipeline By Route of Administration, 2011
Meda AB – Pipeline By Molecule Type, 2011
Meda AB – Recent Pipeline Updates, 2011
Meda AB, Other Locations
Meda AB, Subsidiaries
Meda AB, Deals Summary, 2004 to YTD 2011
Meda AB, Deals Summary by Region, 2004 to YTD 2011
Meda AB, Deals Summary, 2004 to YTD 2011
Meda AB, Deals Summary, 2004 to YTD 2011

List of Figures
Meda AB – Pipeline by Therapy Area and Indication, 2011
Meda AB – Pipeline by Stage of Development, 2011
Meda AB – Monotherapy Products in Pipeline, 2011
Meda AB – Pipeline By Therapeutic Class, 2011
Meda AB - Pipeline By Target, 2011

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Thursday, May 23, 2013
7:38:34 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Meda AB - Product Pipeline Review - Q2 2011

Web Address

http://www.researchandmarkets.com/reports/1861752

Office Code

OC8DIQSOPVSTSQ

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Thursday, May 23, 2013
7:38:34 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Meda AB - Product Pipeline Review - Q2 2011

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)